-
Featured
Innovations in ALS Clinical Trials
Merit Cudkowicz, MD, MSc, chief of Neurology at Massachusetts General Hospital, discusses innovations in ALS clinical trials since she started in the field in 1994.
-
Featured
Advancements in the Treatment of Neurodegenerative Disease
In this video, Ghazaleh Sadri-Vakili, PhD, director of the NeuroEpigenetics Laboratory and the MassGeneral Institute of Neurodegenerative Disease, discusses her genetic research, specifically concerning neurodegenerative diseases like ALS and X-linked dystonia parkinsonism.
-
Featured
Identifying New Potential Therapeutic Targets for ALS FTD
Transcripts of repeat expansions in the C90RF72 gene undergo a repeat-associated non-AUG (RAN) translation pathway that generates multiple aberrant proteins. Researchers at Mass General Hospital identified new potential therapeutic targets for ALS FTD.
-
Mortality from Neurodegenerative Disease Not a Concern in Major League Baseball
All-cause mortality and mortality from neurodegenerative disease are no higher among Major League Baseball than the general population, but playing professional baseball seems to increase mortality from certain cancers.
-
NeuroEpigenetics Lab Clears Path for ALS Breakthrough
Scientists in the NeuroEpigenetics Laboratory in the MassGeneral Institute for Neurodegenerative Disease are working to hasten the development of needed therapeutic interventions for amyotrophic lateral sclerosis.
-
Sean M. Healey & AMG Center for ALS to Evaluate Five Promising Treatments in First ALS Platform Trial
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital will launch a platform trial to evaluate and develop treatments for amyotrophic lateral sclerosis (ALS). The trial may significantly reduce the time to find an effective treatment and decrease costs by a third or more.
ALS contributors
-
Clotilde Lagier-Torurenne, MD, PhD
Assistant Professor of Neurology, Harvard Medical School, Assistant in Neuroscience, Massachusetts General Hospital
Recent Article
Researchers Identify a New Therapeutic Target for TDP-43-mediated Neurodegenerative Diseases
-
Ghazaleh Sadri-Vakili, MS, PhD
Assistant in Neuroscience, Massachusetts General Hospital, Assistant Professor of Neurology, Harvard Medical School
Recent Article
Cromolyn Sodium Provides Neuroprotection in Animal Model of ALS
-
James D. Berry, MD, MPH
Co-director, Multidisciplinary Amyotrophic Lateral Sclerosis (ALS) Clinic
Recent Article
Infusions of Regulatory T Cells Slowed ALS Progression in First-in-Humans Trial
-
Merit Ester Cudkowicz, MD, MSc
Chief, Neurology Service, Director of the Sean M. Healey & AMG Center for ALS at Mass General, Director of Neurological Clinical Research Institute and the Jilieane Dorn Professor of Neurology, Harvard Medical School
Recent Article
Cromolyn Sodium Provides Neuroprotection in Animal Model of ALS
-
Nazem Atassi, MD
Associate Director, Neurological Clinical Research Institute (NCRI), Mass General Hospital, Associate Professor of Neurology, Harvard Medical School
Recent Article
Novel Immunomodulator Safe and Tolerable in Pilot Study for ALS
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.Resource Links
